Plasma cell myeloma
Not recruitingStudy of isatuximab, pomalidomide and dexamethasone combination for multiple myeloma patients who previously received lenalidomide and Proteasome Inhibitor therapy
Study of isatuximab, pomalidomide and dexamethasone combination for multiple myeloma patients who previously received lenalidomide and Proteasome Inhibitor therapy
- Disease:Plasma cell myeloma
- Substances:DexamethasoneIsatuximab+1
Greece- Participants:18–64 years · 65+ years
- Substances:Dexamethasone
- Sponsor:Hellenic Society Of Hematology









